The Effects of Off-label Drug Use on Disability and Medical Expenditure
Author
Abstract
Suggested Citation
Note: EH
Download full text from publisher
Other versions of this item:
- Blankart, Katharina & Lichtenberg, Frank R., 2022. "The effects of off-label drug use on disability and medical expenditure," Ruhr Economic Papers 969, RWI - Leibniz-Institut für Wirtschaftsforschung, Ruhr-University Bochum, TU Dortmund University, University of Duisburg-Essen.
References listed on IDEAS
- Blume-Kohout, Margaret E. & Sood, Neeraj, 2013. "Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development," Journal of Public Economics, Elsevier, vol. 97(C), pages 327-336.
- Daron Acemoglu & Joshua Linn, 2004.
"Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,"
The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 119(3), pages 1049-1090.
- Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
- Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," Levine's Working Paper Archive 228400000000000002, David K. Levine.
- Frank, Richard G. & Zeckhauser, Richard J., 2007.
"Custom-made versus ready-to-wear treatments: Behavioral propensities in physicians' choices,"
Journal of Health Economics, Elsevier, vol. 26(6), pages 1101-1127, December.
- Richard G. Frank & Richard J. Zeckhauser, 2007. "Custom Made Versus Ready to Wear Treatments; Behavioral Propensities in Physician's Choices," NBER Working Papers 13445, National Bureau of Economic Research, Inc.
- W. David Bradford & John L. Turner & Jonathan W. Williams, 2018. "Off‐Label Use of Pharmaceuticals: A Detection Controlled Estimation Approach," Journal of Industrial Economics, Wiley Blackwell, vol. 66(4), pages 866-903, December.
- Strulik, Holger, 2015. "Frailty, mortality, and the demand for medical care," The Journal of the Economics of Ageing, Elsevier, vol. 6(C), pages 5-12.
- Böhm, Sebastian & Grossmann, Volker & Strulik, Holger, 2021.
"R&D-driven medical progress, health care costs, and the future of human longevity,"
The Journal of the Economics of Ageing, Elsevier, vol. 18(C).
- Böhm, Sebastian & Grossmann, Volker & Strulik, Holger, 2017. "R&D-driven medical progess, health care costs, and the future of human longevity," University of Göttingen Working Papers in Economics 325, University of Goettingen, Department of Economics.
- Sebastian Böhm & Volker Grossmann & Holger Strulik, 2018. "R&D-Driven Medical Progress, Health Care Costs, and the Future of Human Longevity," CESifo Working Paper Series 6897, CESifo.
- Mirko Kremer & Brent Moritz & Enno Siemsen, 2011. "Demand Forecasting Behavior: System Neglect and Change Detection," Management Science, INFORMS, vol. 57(10), pages 1827-1843, October.
- Ramkumar Janakiraman & Shantanu Dutta & Catarina Sismeiro & Philip Stern, 2008. "Physicians' Persistence and Its Implications for Their Response to Promotion of Prescription Drugs," Management Science, INFORMS, vol. 54(6), pages 1080-1093, June.
- Jovanovic, Boyan & Yatsenko, Yuri, 2012. "Investment in vintage capital," Journal of Economic Theory, Elsevier, vol. 147(2), pages 551-569.
- Duflos, Gautier & Lichtenberg, Frank R., 2012. "Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization," International Review of Law and Economics, Elsevier, vol. 32(1), pages 95-109.
- Frank R. Lichtenberg, 2014. "The Impact of Pharmaceutical Innovation on Disability Days and the Use of Medical Services in the United States, 1997-2010," Journal of Human Capital, University of Chicago Press, vol. 8(4), pages 432-480.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Frank R. Lichtenberg, 2019. "How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013," NBER Working Papers 25483, National Bureau of Economic Research, Inc.
- Frank R. LICHTENBERG, 2018.
"The Impact of New Drug Launch on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries,"
JODE - Journal of Demographic Economics, Cambridge University Press, vol. 84(3), pages 309-354, September.
- Lichtenberg, Frank R., 2018. "The Impact Of New Drug Launches On Life-Years Lost In 2015 From 19 Types Of Cancer In 36 Countries," Journal of Demographic Economics, Cambridge University Press, vol. 84(3), pages 309-354, September.
- Frank R. Lichtenberg, 2018. "The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries," NBER Working Papers 24536, National Bureau of Economic Research, Inc.
- Frank R. Lichtenberg, 2018. "The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries," Working Papers id:12757, eSocialSciences.
- Anna Chorniy & James Bailey & Abdulkadir Civan & Michael Maloney, 2021. "Regulatory review time and pharmaceutical research and development," Health Economics, John Wiley & Sons, Ltd., vol. 30(1), pages 113-128, January.
- Volker Grossmann, 2021. "Medical Innovations and Ageing: A Health Economics Perspective," CESifo Working Paper Series 9387, CESifo.
- Nicholas Bagley & Benjamin Berger & Amitabh Chandra & Craig Garthwaite & Ariel D. Stern, 2018. "The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century," NBER Chapters, in: Innovation Policy and the Economy, Volume 19, pages 97-137, National Bureau of Economic Research, Inc.
- Beth Woods & James Lomas & Mark Sculpher & Helen Weatherly & Karl Claxton, 2024. "Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required," Health Economics, John Wiley & Sons, Ltd., vol. 33(4), pages 804-819, April.
- Leila Agha & Soomi Kim & Danielle Li, 2020. "Insurance Design and Pharmaceutical Innovation," NBER Working Papers 27563, National Bureau of Economic Research, Inc.
- Caroline S. Bennette & Anirban Basu & Scott D. Ramsey & Zachary Helms & Peter B. Bach, 2017. "Returns to Pharmaceutical Innovation in the Market for Oral Chemotherapy in Response to Insurance Coverage Expansion," NBER Working Papers 23842, National Bureau of Economic Research, Inc.
- Iizuka, Toshiaki & Uchida, Gyo, 2017.
"Promoting innovation in small markets: Evidence from the market for rare and intractable diseases,"
Journal of Health Economics, Elsevier, vol. 54(C), pages 56-65.
- IIZUKA Toshiaki & UCHIDA Gyo, 2016. "Promoting Innovation in Small Markets: Evidence from the market for rare and intractable diseases," Discussion papers 16036, Research Institute of Economy, Trade and Industry (RIETI).
- Hermosilla, Manuel & Wu, Yufei, 2018. "Market size and innovation: The intermediary role of technology licensing," Research Policy, Elsevier, vol. 47(5), pages 980-991.
- Daniel J. Hemel & Lisa Larrimore Ouellette, 2023.
"The Generic Drug Trilemma,"
Entrepreneurship and Innovation Policy and the Economy, University of Chicago Press, vol. 2(1), pages 41-77.
- Daniel J. Hemel & Lisa L. Ouellette, 2022. "The Generic Drug Trilemma," NBER Chapters, in: Entrepreneurship and Innovation Policy and the Economy, volume 2, pages 41-77, National Bureau of Economic Research, Inc.
- Giammario Impullitti & Richard Kneller & Danny McGowan, 2020.
"Demand‐Driven Technical Change and Productivity Growth: Theory and Evidence FROM the Energy Policy Act,"
Journal of Industrial Economics, Wiley Blackwell, vol. 68(2), pages 328-363, June.
- Giammario Impullitti & Richard Kneller & Danny McGowan, 2017. "Demand-driven Technical Change and Productivity Growth: Theory and Evidence from the US Energy Policy Act," Discussion Papers 2017/03, University of Nottingham, Centre for Finance, Credit and Macroeconomics (CFCM).
- Eric Helland & Seth A. Seabury, 2016. "Are Settlements in Patent Litigation Collusive? Evidence from Paragraph IV Challenges," NBER Working Papers 22194, National Bureau of Economic Research, Inc.
- Hermosilla, Manuel, 2024. "Regulating ethical experimentation: Impacts of the breakthrough therapy designation on drug R&D," Journal of Health Economics, Elsevier, vol. 94(C).
- Jeffrey Clemens & Joshua D. Gottlieb, 2017.
"In the Shadow of a Giant: Medicare’s Influence on Private Physician Payments,"
Journal of Political Economy, University of Chicago Press, vol. 125(1), pages 1-39.
- Jeffrey Clemens & Joshua D. Gottlieb, 2013. "In the Shadow of a Giant: Medicare's Influence on Private Physician Payments," NBER Working Papers 19503, National Bureau of Economic Research, Inc.
- David Besanko & David Dranove & Craig Garthwaite, 2016. "Insurance and the High Prices of Pharmaceuticals," NBER Working Papers 22353, National Bureau of Economic Research, Inc.
- Kevin A. Bryan & Heidi L. Williams, 2021. "Innovation: Market Failures and Public Policies," NBER Working Papers 29173, National Bureau of Economic Research, Inc.
- Jeffrey P. Clemens & Parker Rogers, 2020.
"Demand Shocks, Procurement Policies, and the Nature of Medical Innovation: Evidence from Wartime Prosthetic Device Patents,"
CESifo Working Paper Series
8781, CESifo.
- Jeffrey Clemens & Parker Rogers, 2020. "Demand Shocks, Procurement Policies, and the Nature of Medical Innovation: Evidence from Wartime Prosthetic Device Patents," NBER Working Papers 26679, National Bureau of Economic Research, Inc.
- Lichtenberg Frank R., 2018.
"The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis,"
Forum for Health Economics & Policy, De Gruyter, vol. 21(2), pages 1-20, December.
- Frank R. Lichtenberg, 2019. "The impact of new drug launches on hospitalization in 2015 for 67 medical conditions in 15 OECD countries: a two-way fixed-effects analysis," CESifo Working Paper Series 7559, CESifo.
- Agarwal, Ruchir & Gaule, Patrick, 2022.
"What drives innovation? Lessons from COVID-19 R&D,"
Journal of Health Economics, Elsevier, vol. 82(C).
- Ruchir Agarwal & Patrick Gaulé, 2021. "What Drives Innovation? Lessons from COVID-19 R&D," IMF Working Papers 2021/048, International Monetary Fund.
- Agarwal, Ruchir & Gaule, Patrick, 2021. "What Drives Innovation? Lessons from COVID-19 R&D," IZA Discussion Papers 14079, Institute of Labor Economics (IZA).
More about this item
JEL classification:
- I1 - Health, Education, and Welfare - - Health
- L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology; Plastics
NEP fields
This paper has been announced in the following NEP Reports:- NEP-HEA-2022-10-10 (Health Economics)
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nbr:nberwo:30440. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: the person in charge (email available below). General contact details of provider: https://edirc.repec.org/data/nberrus.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.